Back to Search Start Over

Novartis medication reduces early-stage breast cancer recurrence by 25%

Source :
Plus Company Updates. June 2, 2023
Publication Year :
2023

Abstract

Novartis breast cancer drug Kisqali cut the risk of recurrence by 25% in early-stage breast cancer, positioning the Swiss drugmaker to win new patients and challenge strong rival Eli Lilly. [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
Plus Company Updates
Publication Type :
News
Accession number :
edsgcl.755545688